Module 1 Flashcards
Numerator
Number of cases of disease
Denominator
Number of people in a population
Frequency of disease
(N/D)/Time
Population
A group of people who share one or more common feature
Epidemiology
The study of occurrence and causes of disease in groups or populations at one point or over a period of time
PECOT
Population Exposure group (E.G.) Comparison Group (CG) Outcome Timing
EGO
Exposure group occurrence
EGO=a/E.G.
CGO
Comparison Group Occurrence
CGO=b/CG
Incidence
Number of disease events occurring over a period of time
EGO & CGO are called incidence of occurrence
Prevalence
The number of people with a disease who are counted at one point in time
EGO & CGO are called prevalence of occurrence
Numerical Outcomes
A quantifiable value e.g. Heart rate per minute
Categorical Outcome
Specific set of options e.g. Yes/no
Period Prevalence
We measure if the event has occurred during a period and not the number of occurrences
Eg. If an asthma attack has happened in the past year
Point Prevalence
Measure Prevalence of something at one point right now
Eg. Level of nicotine in blood at one point
Ecological Study
Comparing groups of populations rather than groups of individuals
Can be RCT, cross sectional, cohort
Confounding is common
Risk Difference - Absolute Inequalities
EGO-CGO
IF RD = 0 then treatment has no effect
Risk Ratio
EGO/CGO
If RR = 0 effect of treatments are the same
Relative Risk Reduction
If RR is less than 1
Relative Risk Increase
If RR is more than 1
R (RAMBOMAN)
Recruitment
Are participants a representative sample from the known population?
A (RAMBOMAN)
Allocation
Was allocations accurate?
Is confounding involved?
Confounding
Difference between EGO and CGO apart from the main difference being studied
To deal with confounding we divide the study into sub studies so participants with the confounded are all in one study
M (RAMBOMAN)
Maintenance
If possible we randomise the population otherwise we ask about disease
Need to maintain initial exposure/comparison groups
B (RAMBOMAN)
Blind
Unbound study: investigators and patients know who is taking treatment or placebo
Single blind: investigators know, patients do not
Double blind: neither investigator nor patient know